[
    [
        {
            "time": "2018-07-06",
            "original_text": "格隆汇港股聚焦(8.06)︱7月多家券商业绩大增；中芯国际第二季度净利创单季新高，同比暴增644%",
            "features": {
                "keywords": [
                    "券商业绩",
                    "中芯国际",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "半导体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(8.06)︱7月多家券商业绩大增；中芯国际第二季度净利创单季新高，同比暴增644%",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-07",
            "original_text": "A股头条之上市公司（8.7）",
            "features": {
                "keywords": [
                    "A股",
                    "上市公司"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股头条之上市公司（8.7）",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "上海医药：取得T3011（瘤内注射）项目在大中华地区商业化独家权益",
            "features": {
                "keywords": [
                    "上海医药",
                    "T3011",
                    "瘤内注射",
                    "独家权益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药：取得T3011（瘤内注射）项目在大中华地区商业化独家权益",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "BD交易|上海医药与亦诺微医药达成超10亿元合作，交易细节公布！",
            "features": {
                "keywords": [
                    "上海医药",
                    "亦诺微医药",
                    "BD交易",
                    "合作金额"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "BD交易|上海医药与亦诺微医药达成超10亿元合作，交易细节公布！",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "上海医药(02607.HK)：拟出资不超11.5亿元取得新一代的溶瘤HSV病毒产品大中华地区商业化的独家权益",
            "features": {
                "keywords": [
                    "上海医药",
                    "溶瘤HSV病毒",
                    "独家权益",
                    "出资金额"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)：拟出资不超11.5亿元取得新一代的溶瘤HSV病毒产品大中华地区商业化的独家权益",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "上海医药：出资11.5亿元取得新一代的溶瘤HSV病毒产品大中华地区商业化的独家权益",
            "features": {
                "keywords": [
                    "上海医药",
                    "溶瘤HSV病毒",
                    "独家权益",
                    "出资金额"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药：出资11.5亿元取得新一代的溶瘤HSV病毒产品大中华地区商业化的独家权益",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "上海医药(601607.SH)：不超11.5亿元取得T3011(瘤内注射)项目在大中华地区商业化的独家权益",
            "features": {
                "keywords": [
                    "上海医药",
                    "T3011",
                    "瘤内注射",
                    "独家权益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)：不超11.5亿元取得T3011(瘤内注射)项目在大中华地区商业化的独家权益",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "智通港股通占比异动统计|8月6日",
            "features": {
                "keywords": [
                    "港股通",
                    "占比异动",
                    "统计"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通占比异动统计|8月6日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-06",
            "original_text": "两融分析：大盘继续活跃 正泰电器融资盘小幅流入",
            "features": {
                "keywords": [
                    "两融分析",
                    "大盘活跃",
                    "正泰电器",
                    "融资盘流入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "电力设备"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "两融分析：大盘继续活跃 正泰电器融资盘小幅流入",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]